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A large amount of epidemiological evidence suggests that the impact of body weight on
breast cancer risk should be heterogeneous throughout the life-stage of women. At birth,
high weight has been positively associated with an increased risk of breast cancer.While,
the bodymass index (a relative bodyweight; BMI kg/m2) has been inversely associatedwith
breast cancer risk among pre-menopausal women.The inverse trend had been observed in
bothWestern andAsian population, with a relatively lower percentage of obesity and higher
percentage of leanness, suggested that the inverse trend could be explained not only by
the protective impact due to obesity, but also by the increased risk of breast cancer due to
leanness. Among post-menopausal women, however, an elevated BMI has been positively
associated with the development of breast cancer, particularly in the cases of estrogen
receptor-positive (ER+) and progesterone receptor-positive (PR+) tumors. Currently, the
mechanisms underlying the heterogeneous impacts between BMI on breast cancer risk
and the life-stage of women remain poorly understood. We reviewed several proposed
biological mechanisms that may contribute to the various impacts of relative body weight
on breast cancer risk across life-stage. We also discussed the impact of BMI upon the
outcome of endocrine therapy, particularly for aromatase inhibitor, in breast cancer patients.
To prevent breast cancer incidence and recurrence, the desirable BMI of women may differ
throughout their life-stage. To deﬁne the underlying mechanism for the various impacts of
BMI in the context of breast cancer across various female life stages, further studies will
be required.
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The heterogeneous impact of body weight on breast cancer
risk has been reported across the female life stages (Bergstrom
et al., 2001; IARC Working Group on the Evaluation of Cancer-
Preventive Strategies, 2002). High birth weight (>4,000 g/8.5 lb)
has been positively associated with an increased risk of breast
cancer according to the latest results of meta-analysis (Xu
et al., 2009). Although not in all cases (Renehan et al., 2008),
protective inverse associations between high body mass index
(a relative body weight; BMI kg/m2) and breast cancer risk
have been suggested among pre-menopausal women (Weider-
pass et al., 2004; Li et al., 2006; Michels et al., 2006a). Following
menopause, it has been found that a substantial positive associ-
ation exists between BMI and the development of breast cancer
risk, particularly in hormone receptor-positive tumors (Suzuki
et al., 2009).
The underlying mechanisms of these heterogeneous impacts
between BMI on breast cancer risk and female life stage remain
to be fully elucidated. Several plausible biological mechanisms
for these various impacts across life stages have been proposed,
including hormone-related mechanisms, as an increased BMI
Abbreviations: BMI, body mass index; ER, estrogen receptor; PR, progesterone
receptor
could affect levels of steroid hormones such as estrogens and
progesterone. These hormones are known to act as important
mitogens for mammalian epithelial cells (Anderson and Clarke,
2004) and can mediate their morphogenic effects upon the mam-
mary gland through paracrine signaling (Brisken et al., 1998;
Mueller et al., 2002; Mallepell et al., 2006). Growth factor-related
mechanisms have also been proposed.
Here, we review the impact of relative body weight upon breast
cancer risk across women’s life stages. We study females at birth as
well as at pre-menopausal and post-menopausal stages. Addition-
ally, we discuss the impact of BMI on the outcome of endocrine
treatment of breast cancer patients.
BIRTH WEIGHT
Many of previous epidemiological studies had reported a posi-
tive association between birth weight and breast cancer risk. The
results of meta-analyses (Michels and Xue, 2006; Xu et al., 2009)
and a recent population-based, case–control study among Asian-
Americans (Wu et al., 2011) provided a substantially increased
risk of breast cancer with excess birth weight. The magnitude
of the summary of risk estimate according to a dose–response
meta-analysis is a 7% increased risk (95% CI: 2–12%) per each
1-kg increase in birth weight (Xu et al., 2009). Although the
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underlying explanation has not been elucidated yet, one of the
most plausible biological mechanisms is estrogen-related one.
Heavier birth weight may be a proxy indicator of intrauterine
exposure to high levels of estrogen hormones (Trichopoulos, 1990;
Mucci et al., 2003), known to be associated with risk of breast can-
cer development (Pike et al., 1993; Anderson and Clarke, 2004).
Previous epidemiological studies, including the Nurses’ Health
Study (Michels et al., 2006b; Hurley et al., 2011), have reported
stronger positive associations between birth weight and the devel-
opment of breast cancer in estrogen receptor-positive (ER+)
and/or progesterone receptor-positive (PR+) tumors compared
to estrogen-independent tumors. Not all (Vatten et al., 2002), but
birth weight has been positively associated with higher intrauter-
ine estrogen (Petridou et al., 1990), and earlier age at menarche
(Wu et al., 2011) as well as inversely associated with level of α-
fetoprotein (AFP), anti-estrogenic property (Nagata et al., 2006).
These results could support the estrogen-related mechanism. Ele-
vation of steroid hormones with increased birth weight (Petridou
et al., 1990; Nagata et al., 2006) might stimulate a function of
mammary stem cells (MaSC) (Asselin-Labat et al., 2010), and this
might be linked to a subsequent risk for the development of breast
cancer.
In fetal growth, mitogenic activity of the insulin receptor-
mediated insulin action may lead to promotion of tumor growth.
It has also been reported that a positive link exists between growth
factors and birth weight (Vatten et al., 2002). Other proposed
mechanisms include (i) a joint effect of insulin-like growth fac-
tor 1(IGF-1) and estrogens on breast cancer risk (Schernhammer,
2002; Vatten et al., 2002); (ii) a potential link between loss of
genetic imprinting of IGF-2, which could play a role in fetal
growth (Constancia et al., 2002) and breast cancer risk (McCann
et al., 1996; Wu et al., 1997; van Roozendaal et al., 1998). Further,
a function of MaSC should be considered (Asselin-Labat et al.,
2010). It was suggested that MaSC are highly sensitive (Shackle-
ton et al., 2006) to steroid hormone signaling, in spite of a lack of
ER/PR (Asselin-Labat et al., 2006); (iii) an increase of the num-
ber of susceptible MaSC or the stimulation of tumor initiation
through DNA mutations due to excess levels of growth factors
(Michels and Xue, 2006).
PRE-MENOPAUSAL WOMEN
In the early-adult stage (i.e., pre-menopausal), epidemiological
results have revealed a weak, or in some cases, a substantial
inverse association between BMI and breast cancer risk (Ursin
et al., 1995; Lahmann et al., 2004; Weiderpass et al., 2004; Michels
et al., 2006a); these results include cohort studies among Chinese
(Li et al., 2006) and Japanese women (Kawai et al., 2010; Suzuki
et al., 2011). In the Western population, the observed inverse (i.e.,
protective) association could be partly explained by obese-related
preventive mechanisms, such as more frequent anovulatory cycles
(Key and Pike, 1988) and a faster clearance rate of estrogens in
the liver (Siiteri et al., 1982) due to pre-menopausal obesity. These
obese-related preventivemechanisms, however, cannot explain the
epidemiological results among the Asian population, which has
a lower prevalence of obesity compared to Western populations
(Murakami et al., 2009). For example, in the Japanese popula-
tion, a substantial inverse association between level of BMI at age
20 and breast cancer risk has previously been reported in two
prospective cohort studies (Kawai et al., 2010; Suzuki et al., 2011).
This suggests the presence of other favorable biological mecha-
nisms (not obesity-related, but body mass-related) in the early
adult life stage.
After puberty, secondary sexual development generally causes
the ovaries to grow. A subsequent increase in the secretion of ovar-
ian hormones, including estrogens and progesterone, leads to the
normal development of the mammary gland. Estrogens generally
act in thedevelopment of the breast duct. Progesterone, in addition
to estrogen,may also play an important role in the development of
mammary gland lobes. Previous animal studies (Sakakura et al.,
1976, 1979) suggested that fat tissue within the breast mass may
play a critical role in the normal development of mammary gland
lobes during the early adult stage, and this process may occur syn-
ergistically with ovarian hormones (Shyamala, 1999). For young
adult women, insubstantial levels of fat tissue and low levels of
ovarian hormones within the breast bud may provide an obsta-
cle to the maturity of mammary glands during the early adult
stage.
In the early adult stage, a low BMI may indicate a lack of a
mammary fat pad or a deﬁciency of progesterone, which may
promote an accumulation of excessive body fat (Kalkhoff, 1982).
For normal differentiation of the mammary gland, sufﬁcient
levels of mammary fat pads, progesterone, or both, may be
required during early adulthood (Sakakura et al., 1979; Russo et al.,
1982, 2001).
The inverse trendbetweenBMI20 years andbreast cancer risk is
observed both amongWestern population as well as Japanese pop-
ulation. In the light of a relatively low proportion of overweight
among the Japanese female, the observed inverse trend should not
explain that overweight-/obese-related mechanism. The develop-
ment of breast tumor due to leanness needs to be considered as
one of possible explanations.
Previous studies suggested that mammary fat pad might play
a number of vital roles in normal growth, differentiation in
mammary gland morphogenesis epithelial–mesenchymal inter-
action according to animal studies. It has been suggested that
body fat might play an important role in differentiation a nor-
mal mammary development. Recently, Prat and Perou (2009)
have proposed that a distinct link exists between the human
mammary epithelial differentiation hierarchy and tumor sub-
type. They suggested that within the human breast, the process
of mammary epithelial differentiation hierarchy might start with
an undifferentiated ER (−) MaSC that differentiates into pro-
genitors. Through the process of differentiation, the progenitors
lead to the formation of mature cells that are derived from dif-
ferentiated luminal epithelial cells. A previous study reported
a signiﬁcant association between leanness at age 20 and an
increased risk of breast cancer with ER (−) PR (−) tumors
(Suzuki et al., 2011). This result could be explained by imma-
ture differentiation due to a lack of body fat. A low BMI resulted
in a lack of breast fat and/or a low level of ovarian hormones
in the early adult life stage, leading us to hypothesize that a
low BMI is associated with an increased risk of breast cancer.
Additional research is needed for the role of body fat in young
adulthood.
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POST-MENOPAUSAL WOMEN
After menopause, epidemiological evidence found a substantial
positive association betweenBMI andbreast cancer risk (Lahmann
et al., 2004). One of the most plausible and classical biological
explanations is a female hormone-relatedmechanismbecause adi-
pose tissue may be a major source of estrogens (Siiteri, 1987),
which are critical mitogens for mammary epithelial cells (Pike
et al., 1993; Anderson and Clarke, 2004). Previous studies have
provided several potential hormone-related explanations for an
increased risk of breast cancer with excess post-menopausal body
weight, as follows: (1) increased levels of estrogen production
due to aromatization of androgens in peripheral fat tissue (Sii-
teri, 1987; Key et al., 2003) and (2) decreased production of
sex hormone binding globulin due to obesity (Enriori et al.,
1986). These hormone-related mechanisms could increase the
supply of free bioavailable estrogen to breast tissues. In fact, the
observed increased risk of breast cancer with increasing post-
menopausal BMI was apparently attenuated after adjustment for
bioavailable serum estrogen concentration (Key et al., 2003). The
effects of estrogens are mediated through the ER and the PR.
A meta-analysis showed that the substantial positive associa-
tion between post-menopausal BMI and breast cancer risk was
conﬁned to ER+ and PR+ tumors (Suzuki et al., 2009). Fur-
thermore, it is well known that the observed positive association
of post-menopausal BMI with an increased risk of breast cancer
was attenuated among ever-users of post-menopausal exogenous
hormones (Suzuki et al., 2009). These results strongly support
the estrogen-related hypothesis that the substantially increased
risk of breast cancer with an increase in post-menopausal BMI
is mainly the result of the associated increase in bioavailable
estrogens.
An insulin-relatedmechanism could also be one possible expla-
nation for the positive association between post-menopausal
body weight and breast cancer risk. Obesity leads to hyperin-
sulinemia with insulin resistance. Excess glucose levels could
stimulate the cellular proliferation of breast tumors (Yamamoto
et al., 1999).
IMPACT OF BMI ON THE OUTCOME OF ENDOCRINE THERAPY
FOR BREAST CANCER PATIENTS
High BMI and obesity are recognized as independent risk factors
for the development of breast cancer, as well as for an increased
rate of recurrence after primary disease (Morimoto et al., 2002;
Loi et al., 2005; Reeves et al., 2007; Protani et al., 2010). Previous
studies have demonstrated a correlation between high BMI and
poor survival in patients with primary breast cancer (Petrelli et al.,
2002; Calle et al., 2003; Dignam et al., 2003; Whiteman et al., 2005;
Majed et al., 2008; Protani et al., 2010; Ewertz et al., 2011).
The impact of BMI on treatment outcome has also been
reported in patients receiving endocrine therapy. There have
been consistent results indicating that the efﬁcacy of aromatase
inhibitors (AIs) vary with BMI; however, the efﬁcacy of tamox-
ifen is not BMI-dependent. In the ATAC (Arimidex, Tamoxifen,
Alone or in Combination) trial, which compared the efﬁcacy of
anastrozole against tamoxifen as an adjuvant treatment for hor-
mone receptor-positive post-menopausal breast cancer patients,
anastrozole, a non-steroidal AI, was signiﬁcantly less effective in
post-menopausal breast cancer patients with a high BMI, whereas
an equal efﬁcacy of tamoxifen was shown across all BMI levels
(Sestak et al., 2010). Retrospective analyses of the Austrian adju-
vant endocrine trials ABCSG6/6a showed similar results. There
was no difference in DFS and OS between overweight (BMI ≥ 25)
and normal-weight post-menopausal patients when treated with
tamoxifen with or without aminoglutethimide in the ﬁrst 5 years
of ABCSG 6 trial period (Pfeiler et al., 2010). In the ABCSG 6a
trial, 856 patients who were disease free at the end of ABCSG 6
trial were randomly assigned to receive either 3 years of anastrozole
or no further treatment. In normal-weight patients treated with
anastrozole had a signiﬁcant better DFS [hazard ratio (HR) 0.48,
p = 0.018] compared to control patients. However, overweight
patients derived no beneﬁt from anastrozole regarding DFS (HR
0.93, p = 0.68) compared to control patients. Identical results
were also observed in pre-menopausal women in the ABCSG 12
trial in which a signiﬁcant impact of BMI on the efﬁcacy of anas-
trozole plus goserelin, but not of tamoxifen plus goserelin, was
found (Pfeiler et al., 2011). For another non-steroidal AI, letrozole,
a retrospective study by Schmid et al. (2000) analyzing advanced
breast cancer patient showed that patients with a high BMI (≥30)
treatedwith letrozole beneﬁted less thanpatientswith aBMIunder
30 kg/m2. In a recent report from the German BRENDA-cohort
study with 4,636 patients, the group of hormone receptor-positive
post-menopausal patients with a normal or intermediate weight
showed a non-signiﬁcant statistical trend toward a survival beneﬁt
with an AI (the exact AIs were not speciﬁed) compared to tamox-
ifen [recurrence free survival (RFS): p = 0.486; HR = 1.29 (95%
CI: 0.63–2.62)], while obese patients (BMI ≥ 30) tended to beneﬁt
more from tamoxifen [RFS: p = 0.289; HR = 0.65 (95% CI: 0.29–
1.45); Wolters et al., 2012]. In contrast, one retrospective study by
Michaud et al. (2002) did not ﬁnd an effect of BMI on survival
after therapy with anastrozole.
It is reported that estrogen levels are inﬂuenced by body
weight, with overweight patients having higher levels compared to
normal-weight patients (Hankinson et al., 1995; McTiernan et al.,
2003; Mahabir et al., 2006). The conversion of androstenedione
to estrone or estradiol by aromatase in adipose tissue is a major
source of estrogen in post-menopausal women. Aromatization
capacity should be higher in obese patients, and it can therefore
be hypothesized that aromatases in the excess fatty tissue cannot
be fully inhibited by standard dosages of AI.
However, as opposed to anastrozole and letrozole, in the TEAM
trial, in which 5 years of exemestane use was evaluated against
2–3 years of tamoxifen followed by 3–2 years of exemestane,
exemestane was found to be more effective in obese patients than
tamoxifen, although the difference was not statistically signiﬁcant
and was only observed during the ﬁrst 2.75 years, when exemes-
tane and tamoxifen were compared directly (Seynaeve et al., 2010).
Similar observations were observed in the neo-adjuvant exemes-
tane clinical trial, JFMC 34-0601, in Japanese post-menopausal
women. Objective response rates with 6 months of exemestane
treatment were 21.7% in low-BMI patients (BMI < 22), 56.0%
in intermediate-BMI patients (22 ≤ BMI < 25) and 60.6% in
high-BMI patients (BMI ≥ 25), respectively (p = 0.01; Takada
et al., 2011). In a multivariate analysis, low BMI was an indepen-
dent negative predictor of clinical response. It is understandable
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Table 1 | Body mass index (BMI) and outcome in clinical trial with aromatase inhibitor.
Study Population Drug Findings Data Reference
ABCSG 12 Pre-menopausal ANA + GOS Less effective in
higher BMI
DFS; HR vs. normal weight = 1.60 (1.06–2.41) in
BMI > 25
Pfeiler et al. (2011)
ATAC Post-menopausal ANA Less effective in
higher BMI
RFS; HR vs. normal weight = 1.30 (0.91–1.85) in
BMI 30–35, =1.53 (1.01–2.32) in BMI > 35
Sestak et al. (2010)
TEAM (analysis
in 2.75 years)
Post-menopausal EXE More effective in
higher BMI (N.S.)
DFS; HR vs. TAM = 0.99 (0.74–1.31) in BMI
18.5–25, = 0.84 (0.62–1.14) in BMI 25–30, = 0.74
(0.52–1.05) in BMI > 30
Seynaeve et al. (2010)
JFMC 34-0601
(neo-adjuvant)
Post-menopausal EXE Less effective in
lower BMI
ORR; 21.7% in BMI < 22, 56.0% in BMI 22–25,
60.6% in BMI > 25
Takada et al. (2011)
ANA, anastrozole; GOS, goserelin; EXE, exemestane, TAM, tamoxifen; HR, hazard ratio; DFS, disease free survival; RFS, recurrence free survival; ORR, overall
response rate.
FIGURE 1 | Impact of BMI on breast cancer risk according to women’s
life stage. Although body weight control is an effective strategy for
preventing breast cancer, women’s life stages should be considered.
To prevent breast cancer, a low BMI is not recommended during the
pre-menopausal stage; a high BMI is not recommended during the
post-menopausal stage.
thatAIsmight be less effective in patientswith a lowerBMIbecause
of the lower baseline estrogen or aromatization levels in these
patients.
From these observations, one can argue that the differences in
the efﬁcacy of AIs depending on BMI might depend on the type of
AI, i.e., non-steroidal vs. steroidal (Table 1). Although the speciﬁc
mechanism of these differences has not been explained yet, it is
clear that the efﬁcacy of theAI varies according to patient BMI; the
efﬁcacy of tamoxifen, however, does not depend on BMI. Further
study would be warranted to deﬁne the mechanism of the effect
of BMI on AI efﬁcacy, which could lead to selective utilization of
AIs and tamoxifen in post-menopausal women.
CONCLUSION
In summary, the current epidemiological study has provided evi-
dence of the impact of body weight on breast cancer risk across
women’s life stages (Figure 1). Although body weight control
is an effective strategy for primary prevention of breast cancer
among post-menopausal women, such recommendations should
take women’s life stage into account, particularly among young
adult pre-menopausal women. In addition, BMI has impact also
on the prognosis of breast caner patients and responsiveness to
the endocrine therapy with AI. To prevent breast cancer inci-
dence and recurrence, the desirable BMI of women may differ
throughout their life-stage. To deﬁne the underlying mecha-
nism for the various impacts of BMI in the context of breast
cancer across various female life stages, further studies will be
required.
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